Clinical trial
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal…
NCT00284089 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00284089 |
|---|---|
| Title | Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration |
| Official title | Open-label Multicenter, Phase I/II Study Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD) |
| Intervention type | Drug |
| Interventions | Ranibizumab |
| Enrollment | 88 |
| Start date | Apr 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Jan 1, 2009 |
| First posted | Jan 31, 2006 |
| Last update posted | Feb 24, 2011 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: